Product Description
Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that was used in combination with peginterferon and ribavirin in the treatment of chronic hepatitis C, genotype 1. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Boceprevir)
Mechanisms of Action: HCV-NS3/4A Inhibitor,SP
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Brazil | Canada | Chile | Colombia | Dominican Republic | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Morocco | New Zealand | Peru | Philippines | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | Thailand | United Kingdom | Vietnam
Approved Indications: Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic
Known Adverse Events: Dysgeusia | Headache | Anemia
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|